



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 2.11.2021

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th Floor  
Plot No.62, G- Block, Opp Trident Hotel,  
Bandra Kurla Complex, Bandra (E)  
Mumbai — 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 2<sup>nd</sup> November, 2021 -- Reg.

Ref: Disclosure under Regulation 30 and 33 SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Tuesday, 2<sup>nd</sup> November, 2021 had inter-alia transacted and approved the following items of business:

1. Approved the Un-audited Financial Results along with the Segment results for the quarter and half year ended 30<sup>th</sup> September, 2021.
2. Approved the Statement of Assets and Liabilities as at 30<sup>th</sup> September, 2021.
3. Approved the Cash Flow Statement as at 30<sup>th</sup> September, 2021.


We herewith enclose the following:

- A. Un-Audited financial Results, Segment results, the Statement of Assets and Liabilities and Cash Flow statement as at 30<sup>th</sup> September, 2021.
- B. Limited Review Report of the Statutory Auditors for the quarter and half year ended 30<sup>th</sup> September, 2021.

This is for your information and necessary records.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

  
(B. Kumar)  
Chief Financial Officer

The meeting Commenced at 4: 00 PM  
The Meeting Concluded at 5:50 PM

**SIGACHI LABORATORIES LIMITED**  
 Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273  
 Website: www.slllab.com, Email: sigachilaboratories@yahoo.co.in  
 CIN:L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter and Half year Ended 30th September, 2021

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Half-Year ended		Year ended 31.03.2021
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Revenue from operations	100.87	75.26	70.90	176.13	155.51	347.61
2	Other income	6.77	8.49	11.86	15.26	13.40	38.09
3	Total Income (1+2)	107.64	83.75	82.76	191.39	168.91	385.70
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-	-
	d) Employee benefits expense	9.52	6.52	7.24	16.04	12.54	28.97
	e) Finance costs	-	-	-	-	-	-
	f) Depreciation and amortization expense	4.17	4.18	4.14	8.35	8.28	16.58
	g) Other expenses	3.38	3.65	2.15	7.03	4.83	26.50
	Total Expenses	17.07	14.35	13.53	31.42	25.65	72.05
5	Profit/(loss) before exceptional and tax (3-4)	90.57	69.40	69.23	159.97	143.26	313.65
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	90.57	69.40	69.23	159.97	143.26	313.65
8	Tax expense						
	(a) Current tax	8.74	6.43	10.66	15.17	16.41	39.88
	(b) Deferred tax	(0.13)	(0.14)	(1.85)	(0.27)	(1.65)	(1.64)
	Total Tax Expense	8.61	6.29	8.81	14.90	14.76	38.24
9	Profit/(Loss) for the Period (8-9)	81.96	63.11	60.42	145.07	128.50	275.41
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or loss	74.88	94.74	55.07	169.62	213.39	414.42
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.03
	Tax on Items that will not be reclassified to profit or loss	-	-	-	-	-	(0.01)
	(c) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	74.88	94.74	55.07	169.62	213.39	414.44
	Total Comprehensive income (9+10)	156.84	157.85	115.49	314.69	341.89	689.85
11	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	-	-	1,946.19
13	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	1.21	0.93	0.89	2.15	1.90	4.08
	(2) Diluted	1.21	0.93	0.89	2.15	1.90	4.08


 Digitally signed  
 by Tunuguntla  
 Raja Sekhar  
 Date:  
 2021.11.02  
 17:53:17 +05'30'

Segment wise Revenue, Results and Capital Employed for the Quarter & Half year ended 30th September, 2021

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Half-Year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	30.00	20.00	28.50	50.00	47.50	116.50
	b) Investments	77.64	63.75	54.26	141.39	121.41	269.20
	Total	107.64	83.75	82.76	191.39	168.91	385.70
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	107.64	83.75	82.76	191.39	168.91	385.70
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	25.66	15.24	24.20	40.90	38.53	98.56
	b) Investments	77.64	63.75	54.26	141.39	121.41	269.20
	Total	103.30	78.99	78.46	182.29	159.94	367.76
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	12.73	9.59	9.23	22.32	16.68	54.11
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	90.57	69.40	69.23	159.97	143.26	313.65
3	Capital Employed						
	(Segment assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	600.51	659.75	601.43	600.51	601.43	620.95
	b) Investments	2,391.42	2,175.34	1,727.85	2,391.42	1,727.85	2,056.29
	Total	2,991.93	2,835.09	2,329.28	2,991.93	2,329.28	2,677.24

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 2nd November, 2021. These financial results are also available on the website of Metropolitan Stock Exchange of India Limited (www.msei.in) and also on the website of the Company (www.slilab.com).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The outbreak of COVID-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a significant decrease in the economic activities. The second wave of covid -19 and the extended lockdown during the First Quarter of the Financial year 2021-2022 has impacted the Company's investments as at September 30, 2021, however the Company believes that it has taken into account all the possible impact of known events arising out of COVID-19 pandemic in the preparation of financial results resulting out of fair valuation of these investments. However the impact assessment of COVID-19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes to future economic conditions.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board  
for SIGACHI LABORATORIES LIMITED

Tunuguntla Raja Sekhar  
Digitally signed by  
Tunuguntla Raja Sekhar  
Date: 2021.11.02  
12:53:36 +05'30'

(T.R.Sekhar)  
Executive Director  
DIN:02943146

Place :Hyderabad  
Date :2.11.2021



**SIGACHI LABORATORIES LIMITED**

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313.  
 Gunmadidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Assets and Liabilities as at 30th September, 2021.

(Rs. In Lakhs)

Particulars	As at 30.09.2021	As at 31.03.2021
<b>A. ASSETS</b>		
<b>1. Non-Current Assets</b>		
(a) Property, Plant and Equipment	238.71	245.79
(b) Financial Assets		
(i) Investments	2,167.42	1,887.13
(ii) Other Financial Assets	43.53	43.53
(c) Other non Current Assets	268.01	-
<b>Total Non - Current Assets</b>	<b>2,717.67</b>	<b>2,176.45</b>
<b>2. Current Assets</b>		
(a) Financial Assets		
(i) Investments	39.03	38.39
(ii) Trade Receivables	9.21	-
(iii) Cash and Cash Equivalents	57.67	242.97
(iv) Other Financial Assets - Loans	224.00	169.16
(b) Other Current Assets	19.00	111.18
<b>Total Current Assets</b>	<b>348.91</b>	<b>561.70</b>
<b>Total Assets</b>	<b>3,066.58</b>	<b>2,738.15</b>
<b>B. EQUITY AND LIABILITIES</b>		
<b>1. Equity</b>		
(a) Equity Share Capital	731.06	731.06
(b) Other Equity	2,260.87	1,946.18
<b>Total Equity</b>	<b>2,991.93</b>	<b>2,677.24</b>
<b>2. Liabilities</b>		
<b>Non-Current Liabilities</b>		
(a) Financial Liabilities	-	-
(b) Long term Provisions	-	-
(c) Deferred Tax Liabilities (net)	17.41	17.68
(d) Other non - Current Liabilities	25.00	25.00
<b>Total Non - Current Liabilities</b>	<b>42.41</b>	<b>42.68</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	-	-
(iii) Other Financial Liabilities	12.78	13.94
(b) Provisions	19.46	4.29
(c) Other Current Liabilities	-	-
<b>Total Current Liabilities</b>	<b>32.24</b>	<b>18.23</b>
<b>Total Equity and Liabilities</b>	<b>3,066.58</b>	<b>2,738.15</b>

for SIGACHI LABORATORIES LIMITED

Digitally signed by  
 Tunuguntla  
 Raja Sekhar  
 DN: cn=Tunuguntla Raja  
 Sekhar, o=SIGACHI LABORATORIES LIMITED, ou=, email=tunuguntla.raja.sekhar@sigachilab.com, c=IN, serial=175888, version=3

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 2.11.2021

**SIGACHI LABORATORIES LIMITED**

Cash Flow Statement For the half year ended 30th September, 2021.

(Rs. in Lakhs)

Particulars	For the Half year ended		For the Year Ended
	30.09.2021	30.09.2020	31.03.2021
<b>Cash Flows from Operating Activities</b>			
Profit before tax	159.97	143.26	313.65
Adjustments for :			
Depreciation and amortization expense	8.35	8.28	16.58
Dividend Received	(7.60)	(7.17)	(28.13)
Provision for Gratuity & Leave Encashment	-	-	2.35
Bad Debts Recovery	(0.88)	-	-
Interest Received	(32.15)	(43.44)	(69.69)
Fair Value (Gains)/Losses	(100.76)	(77.97)	(171.39)
Operating profit before working capital changes	26.93	22.96	63.37
Movements in Working Capital			
(Increase)/Decrease in Trade Receivables	(9.21)	1.12	20.85
(Increase)/Decrease in Other Financial Assets	(54.84)	(0.48)	3.13
(Increase)/Decrease in Other Current Assets	107.46	(31.55)	(35.13)
(Increase)/Decrease in Other Non Current Assets	(268.01)	-	-
Increase/(Decrease) in Other Financial Liabilities	(1.17)	(5.76)	0.97
Changes in Working Capital	(225.77)	(36.67)	(10.18)
<b>Cash generated from operations</b>	(198.84)	(13.71)	53.19
Direct Taxes Paid	15.27	12.67	38.10
<b>Net Cash from operating activities (A)</b>	(214.11)	(26.38)	15.09
<b>Cash Flows from Investing Activities</b>			
(Purchase) of Property, Plant & Equipment	(1.27)	-	(0.71)
(Purchase)/Sale of Investments (Net Aggregate)	(92.42)	(32.09)	(60.48)
Dividend Received	7.60	7.17	28.13
Bad Debts Recovery	0.88	-	-
Interest Received	32.15	43.44	69.69
(Increase)/Decrease in other term deposits	81.87	(8.77)	(18.92)
<b>Net Cash used in Investing Activities (B)</b>	28.81	9.75	17.71
<b>Cash Flows from/(used in) Financing Activities</b>			
Proceeds from Long term borrowings	-	-	-
Repayment/(Proceeds) of/from Short-term borrowings	-	-	-
Dividend paid	-	-	-
<b>Net Cash used in Financing Activities (C)</b>	-	-	-
<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	(185.30)	(16.63)	32.80
Cash and Cash Equivalents at the beginning of the year	242.97	210.17	210.17
Cash and Cash Equivalents at the ending of the year	57.67	193.54	242.97

for SIGACHI LABORATORIES LIMITED

Digitally signed by  
Tunuguntla Raja Sekhar  
Raja Sekhar  
Date: 2021.11.02  
17:54:14 +05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 2.11.2021



# niranjan & narayan

Chartered Accountants

FRN : 005899S  
GSTIN : 36AACFN0604K1ZJ

first floor, h.no: 7-1-28/1/A/21  
shyamkaran road, ameerpet  
hyderabad - 500016  
tel : 040-29806074  
email : caniranjan@yahoo.com  
www.nncas.com

## INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To  
The Board of Directors,  
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sigachi Laboratories Limited** ("the company") for the quarter and six months ended 30<sup>th</sup> September, 2021 ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 02.11.2021



For Niranjan & Narayan  
Chartered Accountants  
FRN:005899S

  
M. Niranjan  
Partner.Memb.No.029552  
UDIN: 21029552AAAAKE605